@entity31016 ( @entity15437 ) is a @entity519 -specific PET tracer. In future clinical applications of @entity519 imaging, such as early response monitoring or radiation therapy dose painting, accurate quantification of tracer uptake at the voxel level will be required. The aim of the present study was to assess the validity of parametric methods for the quantification of @entity8984 -FAZA studies. METHODS: Dynamic 70-min @entity15437 scans were obtained from 9 @entity1149 @entity1 . Arterial blood samples, collected at 7 time points, were used for preprocessing an image-derived input function derived from volumes of interest (VOIs) defined within the ascending aorta. Time-activity curves derived from various @entity5 VOIs were fitted using nonlinear regression analysis (NLR) to a reversible 2-tissue-compartment model, providing volumes of distribution (VT) as an outcome measure. Next, parametric images were generated by use of both Logan graphic analysis with various linear regression start times and spectral analysis with multiple sets of basis functions. The previously defined @entity5 VOIs were projected onto these parametric images, and the resulting VT were compared with those obtained from NLR. In addition, the results were compared with @entity5 (SUVr), which are more easily obtainable. RESULTS: The highest correlations and correspondence with NLR-derived VT were found for Logan graphic analysis with a start time of 30 min after injection (R(2), 0.88; intraclass correlation coefficient [ICC], 0.93) and for spectral analysis-derived VT with a set of 30 basis functions with exponents ranging from 0.0175 to 1.9 (R(2), 0.79; ICC, 0.81). SUVr yielded similar correlations but showed significant bias at high VT (R(2), 0.85; ICC, 0.80). CONCLUSION: Both Logan graphic analysis and spectral analysis yielded VT that showed high correlations with nonlinear regression analysis-derived VT. SUVr showed bias at high VT.

Parametric Methods for Quantification of XXXX Kinetics in @entity1149 @entity1 .

@entity8984 :: ('CHEBI:36939', 'Chemical') :: ['(18)F'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity31016 :: ('MESH:C498052', 'Chemical') :: ['(18)F-fluoroazomycinarabinoside'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumor-to-blood ratios'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity15437 :: ('MESH:C498052|MESH:C549903', 'Chemical') :: ['(18)F-FAZA'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia']
@entity15437 :: (MESH:C498052|MESH:C549903,Chemical) :: ['18F-FAZA']
